ENTA - NASDAQ
Enanta Pharmaceuticals, Inc.
$12.03
-6.6%Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
At a Glance
Live SnapshotEnanta Pharmaceuticals, Inc. Management Team
Mr. Brendan Luu
Chief Business Officer
Compensation
$622,856
Mr. Paul J. Mellett Jr.
Chief Financial & Administrative Officer
Compensation
$671,700
Mr. Matthew P. Kowalsky J.D.
Chief Legal Officer & Corporate Secretary
Compensation
$575,652
Dr. Scott T. Rottinghaus M.D.
Chief Medical Office
Compensation
$776,138
Ms. Tara Lynn Kieffer Ph.D.
Chief Product Strategy Officer
Compensation
$496,852
Dr. Yat Sun Or Ph.D.
Chief Scientific Officer
Compensation
$740,108
Mr. Nathaniel S. Gardiner J.D.
Consultant
Compensation
$672,675
Ms. Jennifer Viera
Executive Director of Investor Relations & Corporate Communications
Dr. Jay R. Luly Ph.D.
President, Chief Executive Officer & Director
Compensation
$1,231,428
Enanta Pharmaceuticals, Inc. Insider Positioning
During the last 12 months, insiders have sold $337K worth of ENTA shares, with no buying activity reported.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
12.9K
183.16K
-183K
-$183K
9-12 Months
0
0.00
17.9K
154.02K
-154K
-$154K
Top Buyers
No buying activity
Top Sellers
Trout Harry R. Iii
Officer: See Remarks
$103K
Luly Jay R.
Director, Officer: President And Ceo
$67K
Capps Kathleen S.
Officer: See Remarks
$56K
Or Yat Sun
Officer: Chief Scientific Officer
$34K
Kieffer Tara Lynn
Officer: Chief Product Strategy Officer
$30K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $337K net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Insider Participation
5 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
SEC Filings
ENTA - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | January 26, 2026 | March 11, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | January 27, 2025 | March 13, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | January 26, 2024 | March 06, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | January 20, 2023 | March 02, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | January 21, 2022 | March 03, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | January 21, 2021 | March 02, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | January 17, 2020 | February 26, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | January 18, 2019 | February 28, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | January 19, 2018 | February 28, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | January 06, 2017 | February 16, 2017 | 2017 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.